Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ipsen S.A. stock logo
IPSEY
Ipsen
$28.55
+0.2%
$28.52
$25.11
$34.06
$9.57B0.545,408 shs441 shs
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$79.78
+1.2%
$97.57
$75.00
$126.89
$5.46B0.23981,578 shs1.23 million shs
Neogen Co. stock logo
NEOG
Neogen
$6.56
+2.8%
$6.82
$3.87
$18.58
$1.42B1.833.01 million shs5.32 million shs
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
$33.03
-1.5%
$31.02
$23.77
$49.45
$2.23B0.131.07 million shs1.40 million shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ipsen S.A. stock logo
IPSEY
Ipsen
+0.07%-7.98%+3.53%-1.45%-15.03%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
-0.18%-2.13%-22.83%-3.84%+0.14%
Neogen Co. stock logo
NEOG
Neogen
-1.69%+7.59%+18.15%-35.69%-51.26%
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
-5.52%+29.78%+22.98%-19.45%-24.06%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ipsen S.A. stock logo
IPSEY
Ipsen
N/AN/AN/AN/AN/AN/AN/AN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
4.4281 of 5 stars
3.51.00.04.23.22.51.9
Neogen Co. stock logo
NEOG
Neogen
3.295 of 5 stars
3.31.00.00.02.63.32.5
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
4.6951 of 5 stars
3.24.00.03.83.41.72.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ipsen S.A. stock logo
IPSEY
Ipsen
3.00
BuyN/AN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
3.00
Buy$132.6766.29% Upside
Neogen Co. stock logo
NEOG
Neogen
2.50
Moderate Buy$9.0037.20% Upside
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
2.43
Hold$44.3334.22% Upside

Current Analyst Ratings Breakdown

Latest IPSEY, LNTH, QDEL, and NEOG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$127.00 ➝ $117.00
5/8/2025
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$45.00 ➝ $29.00
5/8/2025
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$44.00
4/22/2025
Neogen Co. stock logo
NEOG
Neogen
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$6.40 ➝ $5.00
4/21/2025
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$38.00 ➝ $25.00
4/14/2025
Neogen Co. stock logo
NEOG
Neogen
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$13.00 ➝ $6.50
4/10/2025
Neogen Co. stock logo
NEOG
Neogen
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $13.00
4/2/2025
Ipsen S.A. stock logo
IPSEY
Ipsen
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/21/2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$127.00 ➝ $122.00
2/27/2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$120.00 ➝ $127.00
(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ipsen S.A. stock logo
IPSEY
Ipsen
$3.87B2.47N/AN/AN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.54B3.56$6.66 per share11.98$11.91 per share6.70
Neogen Co. stock logo
NEOG
Neogen
$906.00M1.57$0.67 per share9.80$14.52 per share0.45
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
$2.78B0.80$25.60 per share1.29$44.75 per share0.74
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ipsen S.A. stock logo
IPSEY
Ipsen
$374.34MN/A0.009.91N/AN/AN/AN/A7/31/2025 (Estimated)
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$326.66M$3.5213.2712.64N/A28.57%44.29%23.52%7/30/2025 (Estimated)
Neogen Co. stock logo
NEOG
Neogen
-$9.42M-$2.23N/A13.39N/A-52.12%2.89%1.98%7/29/2025 (Estimated)
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
-$2.03B-$4.97N/A10.29N/A-72.84%3.78%1.80%7/30/2025 (Estimated)

Latest IPSEY, LNTH, QDEL, and NEOG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.64$1.53-$0.11$1.02$377.37 million$372.76 million
5/7/2025Q1 2025
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
$0.61$0.74+$0.13-$0.19$694.97 million$692.80 million
4/9/2025Q3 2025
Neogen Co. stock logo
NEOG
Neogen
$0.12$0.10-$0.02-$0.05$225.27 million$221.00 million
2/27/2025Q4 2024
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.57$1.34-$0.23-$0.17$376.61 million$391.11 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ipsen S.A. stock logo
IPSEY
Ipsen
$0.210.74%N/AN/AN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
N/AN/AN/AN/AN/A
Neogen Co. stock logo
NEOG
Neogen
N/AN/AN/AN/AN/A
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ipsen S.A. stock logo
IPSEY
Ipsen
N/A
1.14
0.98
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
N/A
1.65
1.56
Neogen Co. stock logo
NEOG
Neogen
0.33
3.77
2.46
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
0.71
1.22
0.69

Institutional Ownership

CompanyInstitutional Ownership
Ipsen S.A. stock logo
IPSEY
Ipsen
N/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
99.06%
Neogen Co. stock logo
NEOG
Neogen
96.73%
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
99.00%

Insider Ownership

CompanyInsider Ownership
Ipsen S.A. stock logo
IPSEY
Ipsen
N/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
1.50%
Neogen Co. stock logo
NEOG
Neogen
1.13%
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
0.79%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ipsen S.A. stock logo
IPSEY
Ipsen
5,325335.26 millionN/ANot Optionable
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
70068.48 million68.48 millionOptionable
Neogen Co. stock logo
NEOG
Neogen
2,110217.04 million214.49 millionOptionable
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
7,00067.46 million66.58 millionOptionable

Recent News About These Companies

QuidelOrtho (NASDAQ:QDEL) Shares Gap Up on Earnings Beat
Brokerages Set QuidelOrtho Co. (NASDAQ:QDEL) PT at $46.83

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Ipsen stock logo

Ipsen OTCMKTS:IPSEY

$28.55 +0.07 (+0.25%)
As of 09:55 AM Eastern

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.

Lantheus stock logo

Lantheus NASDAQ:LNTH

$79.78 +0.97 (+1.23%)
As of 04:00 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Neogen stock logo

Neogen NASDAQ:NEOG

$6.56 +0.18 (+2.82%)
As of 04:00 PM Eastern

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods. The segment offers its products primarily to milling and grain, meat and poultry, prepared foods and ingredients, fruits and vegetables, seafood, dairy, beverage, water, healthcare, traditional culture media markets, food service, and dietary supplements markets. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products, and genomics testing services marketed through veterinarians, retailers, livestock producers, and animal health product distributors, for the animal safety market. The segment offers its products for companion animal veterinarians; livestock producers, veterinarians, and breed associations; retailers; breeding and genetics companies; diagnostic labs and universities; distributors; and other manufacturers and government agencies. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.

QuidelOrtho stock logo

QuidelOrtho NASDAQ:QDEL

$33.03 -0.52 (-1.55%)
As of 04:00 PM Eastern

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.